Johnson & Johnson

Latest Headlines

Latest Headlines

J&J leads $24M financing into maker of OTC 'liquid shots' for common ailments

Johnson & Johnson's venture arm just led a $24 million Series C financing of First Aid Shot Therapy, the maker of over-the-counter 40-ml "liquid shots" for relief of pain, colds, heartburn and hangovers.

J&J enters market for implants to prevent stroke via acquisition of Coherex Medical

Johnson & Johnson's Biosense Webster added to its antistroke offerings with the acquisition of Salt Lake City's Coherex Medical, maker of the CE-marked Coherex WaveCrest Left Atrial Appendage Occlusion System, for an undisclosed sum.

J&J undercuts Celgene's Pomalyst with $135K-per-year Darzalex price

Johnson & Johnson's new multiple myeloma treatment Darzalex (daratumumab) scored a speedy FDA approval, entering a market that's already crowded with last-ditch treatments. But the company is hoping an impressive response rate will help the new med knock aside Celgene's Pomalyst and Amgen's Kyprolis in the battle for market share.

J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex

Johnson & Johnson scored an early FDA approval for its "breakthrough" blockbuster contender daratumumab, earning a swift OK as a new treatment for multiple myeloma four months ahead of the PDUFA date. The drug will be marketed as Darzalex.

J&J to launch suite of orthopedics 'solutions' for outpatient joint replacement

Johnson's & Johnson's DePuy is launching a comprehensive program to optimize outpatient joint replacement at U.S. ambulatory surgical centers and outpatient hospitals that includes physician training, an educational video for patients to facilitate postoperative recovery and software for outcomes data collection, all in an effort to increase patient satisfaction by getting them home faster.

J&J unveils the first major blood glucose monitor to support Apple HealthKit

Blood glucose monitor manufacturers are working to make their data easily accessible and analyzable by patients and healthcare providers. But that's a tall order for this industry segment, which has historically been focused on making tracking easier, cheaper and more convenient rather than more useful.

UPDATED: J&J slapped with $1.75M verdict in Risperdal breast growth case

Johnson & Johnson lost another courtroom battle over claims that the company failed to warn doctors and patients that its antipsychotic drug Risperdal could cause breast growth in boys, a blow for the company as it continues to deal with related cases.

Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials

Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.

UPDATED: Chicago makes second run at Allergan, J&J, Purdue and others with painkiller lawsuit

Opioid makers thought they had dodged a litigation bullet 6 months ago when a federal judge dismissed a lawsuit by the City of Chicago trying to hold them accountable for an "epidemic" of painkiller, and even heroin, abuse. But the city is being tenacious and has refiled lawsuits claiming 6 drugmakers overstated the claims of the drugs' benefits while downplaying their risks.

J&J deepens its antiviral pipeline with Novira buyout

Johnson & Johnson is trading an undisclosed sum for private drugmaker Novira Therapeutics, picking up an early-stage treatment for hepatitis B and a handful of antivirals.